Journal of Renal and Hepatic Disorders 2018-11-13T22:56:30-08:00 Managing Editor Open Journal Systems <p><img style="padding-right: 15px; padding-bottom: 15px; float: left;" src="/public/site/images/jdisord/Jrenhep_logo_png_1001.png">Journal of Renal and Hepatic Disorders is a peer-reviewed, online-only, open access journal that publishes basic science and clinical research articles on disorders of the kidneys and the liver. In addition to considering disorders of each organ separately, the journal aims to be a scholarly forum for discussing how disorders of one organ influence the other. Chronic liver disease is associated with primary and secondary kidney diseases. Similarly, renal disorders are associated with hepatic disorders. Original articles, reviews and case reports on any aspects of kidneys and liver are suitable for submission.</p> Potassium Profiling in Hemodialysis 2018-11-13T22:56:30-08:00 Nikhil Agrawal Sahil Agrawal Nishita Tripathi Mark Segal Cardiac dysrhythmia and sudden death account for a large proportion of cardiac mortality in dialysis patients. Risk factors for sudden death that are specific to dialysis patients include fluid and electrolyte imbalances during hemodialysis, particularly those of potassium. The risk of arrhythmia may be related to changes in serum K+ concentration during dialysis, and thus close attention should be paid to the dialysate K+ concentration and the serum–dialysate concentration gradient. Potassium profiling is a technique where the dialysate K+ concentration is gradually reduced to keep the gradient between blood and dialysate at a non-fluctuating low level. We provide a review of studies that compare constant potassium concentration in dialysate to gradual reduction in dialysate potassium concentration. These studies illustrate that adequate and more gradual potassium removal can be achieved with potassium profiling techniques, while having lower cardiac irritability. 2018-08-07T03:27:30-07:00 ##submission.copyrightStatement## Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV 2018-08-07T03:28:39-07:00 Nicole Marie Lioufas Alan Street Paul Champion de Crespigny Stephen G Holt <p>Tenofovir disoproxil fumarate (TDF) is a common antiretroviral utilised in the treatment of human immunodeficiency virus (HIV) and hepatitis B infections. It is associated with the development of tubulotoxicity and tubulopathies, and is not recommended in the treatment of patients with baseline chronic kidney disease. Until now, guidelines have suggested frequent monitoring of serum biochemistry to detect the development of such complications. In recent trials, a new prodrug formulation of tenofovir alafenamide (TAF) has been shown to exhibit less tubular toxicity than its counterpart due to a lower serum concentration of its metabolites. In this article, we share our experience with two patients who developed tubulotoxicity following the commencement of TDF-based regimens in HIV, and its improvement following its change to TAF, and review the available literature regarding tenofovir-based nephrotoxicity.</p> 2018-06-30T08:25:22-07:00 ##submission.copyrightStatement##